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Objective: This study evaluated the effect of pedal arch quality on the amputation-free survival and patency rates of distal
bypass grafts and its direct impact on the rate of healing and time to healing of tissue loss after direct angiosome
revascularization in patients with critical limb ischemia (CLI).
Methods: Between 2004 and 2011, patients undergoing distal bypass for CLI (Rutherford 4-6) were divided in groups
taking into consideration the state of the pedal arch and direct angiosome revascularization (DAR) and non-DAR.
Angiography was used to divide the pedal arch into three groups: complete pedal arch (CPA), incomplete pedal arch
(IPA), and no pedal arch (NPA). The primary end points were patency rates at 12 months, amputation-free survival at
48 months, and the rate of healing and time to healing of foot tissue loss.
Results: A total of 154 patients (75% men) with CLI underwent 167 infrapopliteal bypasses. Patients were a median age of
75 years (range, 46-96 years). Diabetic mellitus was present in 76%, chronic renal failure in 28%, and ischemic heart
disease in 44%. The primary patency rates at 1 year in the CPA, IPA, and NPA groups were 58.4%, 54.6%, and 63.8%,
respectively (P [ .5168), the secondary patency rates were 86.0%, 84.7%, and 88.8%, respectively (P [ .8940), and the
amputation-free survival at 48 months was 67.2%, 69.7%, and 45.9%, respectively (P[ .3883). Tissue loss was present in
141 of the 167 bypasses. In the CPA group, 83% of tissue loss with DAR healed compared with 92% in the non-DAR
(median time to healing, 66 vs 74 days). Similarly in the IPA group, 90% with DAR healed compared with 81% in the
non-DAR (median time to healing, 96 vs 86 days). In the NPA group, only 75% with DAR healed compared with 73% in
the non-DAR (median time to healing, 90 vs 135 days). There was a signiﬁcant difference in healing and time to healing
between the CPA/IPA and NPA groups (P [ .0264).
Conclusions: The quality of the pedal arch did not inﬂuence the patency or the amputation-free survival rates. However,
the rates for healing and time to healing were directly inﬂuenced by the quality of the pedal arch rather than the
angiosome revascularized. (J Vasc Surg 2013;57:1219-26.)2An angiosome is a “block of tissue supplied by a named
artery whose territories in the integument and the under-
lying deep tissue correspond,” as described by Taylor and
Palmer1 in an elaborate publication in 1987. Five distinc-
tive angiosomes were described in the leg and foot territory
and are supplied by the anterior tibial, peroneal, and poste-
rior tibial arteries, with its terminal branches, the medial
and lateral planter arteries.
This angiosome concept has generated great interest,
with studies extrapolating this model on the treatment of
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://dx.doi.org/10.1016/j.jvs.2012.10.129In 2006, Attinger et al published their study looking
into the clinical implications of foot and ankle angiosomes
on revascularization and limb salvage. Since then, several
reports have been published supporting the angiosome
concept on healing patients with CLI by open bypass
surgery3 or endovascular intervention.4,5
Infrapopliteal and pedal arterial bypass are now ﬁrmly
established techniques in the treatment of patients with
CLI. However, there is still scarce evidence concerning
the effect of the quality of the pedal arch on the outcome
of distal bypass grafts in these patients. Although studies
addressing the concept of foot angiosome revascularization
have been published,2-5 we are not aware of any studies
looking at the effect of direct angiosome revascularization
(DAR) in the presence of a complete or incomplete pedal
arch (IPA) after crural or pedal bypass. The aim of this study
was to evaluate the effect of pedal arch quality on the
amputation-free survival and patency rates of infrapopliteal
bypass grafts and its direct effect on the rate of healing and
time to healing of tissue loss after DAR in patients with CLI.
METHODS
This was a retrospective analysis of prospectively
collected data. All patients undergoing infrapopliteal
bypass between 2004 and 2011 at a single tertiary vascular1219
Fig 1. Complete pedal arch (CPA).
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all patients was CLI, (Rutherford category 4, 5, and 6)
secondary to long occlusive femoropopliteal disease or
trifurcation disease (TransAtlantic Inter-Society Consensus
[TASC] type C and D classiﬁcation for femoropopliteal
disease) or both,6 requiring infrapopliteal bypass surgery
as determined by digital subtraction angiography (DSA).
Patient risk factors, including diabetes mellitus, chronic
renal failure (deﬁned as serum creatinine baseline $120
mmol/L), hypertension, history of symptomatic ischemic
heart disease and smoking were documented. Data of clin-
ical presentation, operative details, and follow-up were
recorded and entered prospectively into an Excel database
(Microsoft Corp, Redmond, Wash) and were analyzed
retrospectively for this study.
Patients presenting with CLI were assessed according
to an established protocol at our center. The protocol
includes clinical assessment of the foot tissue loss and the
vascular status of the leg. All patients underwent a detailed
arterial duplex scan with distal waveforms analysis. A dedi-
cated foot duplex assessment was also performed in
selected patients to look speciﬁcally into the pedal arteries
and arch size and amount of calciﬁcation. Because a large
proportion of these patients with CLI are diabetic with
chronic renal failure, we did not routinely use ankle-
brachial pressure index in the ischemia assessment due to
unreliable readings in these patients.
Our policy is to operate on patients on clinical presen-
tation and presence of damped waveforms in the crural and
pedal vessels. The target runoff vessel for the bypass is
selected on the basis of anatomic and clinical factors to
restore a straight-line ﬂow to the area of ischemia following
the angiosome principle.
Conventional DSA was obtained to delineate the
anatomy of the infrapopliteal arterial system with dedicated
pedal arch images taken in two planes to fully delineate the
state of the arch. Planned inﬂow angioplasty was performed
before surgical intervention should there be a stenotic
lesion of >50% proximal to the site of the proposed prox-
imal anastomosis.
The preoperative DSA was used to classify the pedal
arch into three groups: the complete pedal arch (CPA;
Fig 1), when both the dorsalis pedis artery and at least
one of the plantar arteries are present and joined by the
deep plantar artery or the ﬁrst dorsal metatarsal artery; the
IPA (Fig 2), when the dorsalis pedis artery or one of the
plantar arteries are present; and no pedal arch (NPA;
Fig 3), when neither the dorsalis pedis nor the plantar
arteries are present but the foot ﬂow is through collateral
circulation. Five patients underwent on-table exploration
of pedal vessels of which two could not be bypassed and
were excluded from any further analysis. The remaining
three patients were included in the NPA group.
Patients only undergoing distal bypass for foot tissue
loss were divided into two groups: the DAR group, where
the perfused angiosome artery matched that of the foot
tissue loss; and the non-DAR group, when the artery
perfused did not match the tissue loss angiosome.We divided the foot angiosomes into three groups
based on Neville et al.3 DAR bypasses were to the anterior
tibial artery for a dorsal foot ulcer, bypass to the peroneal
artery for a lateral ankle ulcer, and bypass to the posterior
tibial artery for an ulcer at the medial plantar instep. An
ulcer on the plantar heel was considered in the DAR group
if the bypass was to the peroneal artery or posterior tibial
artery.
Each ulcer was graded using the Wagner wound classi-
ﬁcation system.7,8 Wounds were debrided urgently before
revascularization if there was a clinical need such as wet
gangrene, pus collection, or extensive infected necrosis.
Otherwise, wound debridement or minor amputations
were performed during bypass surgery. Wounds were
treated with appropriate topical wound care. Large wounds
(>7 cm in diameter) underwent split-thickness skin grafts
(SSG) to achieve faster wound coverage. Vacuum-assisted
closure (VAC; Kinetic Concepts Inc, San Antonio, Tex)
was liberally used in postdebridement wounds as well as
after SSGs.
The great saphenous vein was used as the preferred
conduit of choice. Polytetraﬂuoroethylene grafts were
used when no suitable superﬁcial vein could be detected.
Preoperative duplex imaging for superﬁcial vein assessment
and mapping was performed in all patients according to
a standard protocol. The smallest vein conduit used was
2 mm in internal diameter. This has been shown to have
good patency rate in infrainguinal bypasses.9
All distal bypass grafts followed a standard surgical
procedure as well as graft surveillance protocol.10
Postoperative anticoagulation was maintained using
a therapeutic dose of low-molecular-weight heparin (Clex-
ane; Sanoﬁ Winthrop Industrie S.A., Ambarès-et-Lagrave,
Fig 2. A, Incomplete pedal arch (IPA) with dorsalis pedis arch only. B, IPA with plantar arch only.
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once daily) in all bypass patients and maintained
throughout the in-hospital period.
Antiplatelet and statin therapy were initiated preopera-
tively and maintained postoperatively. Patients undergoing
ultradistal bypasses received dual antiplatelet therapy. Such
regimen was the same for prosthetic as well as autogenous
grafts.
Bypasses were divided into CPA, IPA, or NPA groups
according to the state of the pedal arch. Each group was
analyzed separately, and the outcomes were compared.
The primary end points were amputation-free survival at
48 months and primary, assisted-primary, and secondary
patency rates of the bypass leg at 12 months for all patients.
The clinical outcome for each foot wound was also assessed
and divided into healed, when full skin closure was
achieved, or nonhealed, which included patients who
died with active wounds. The effect of DAR and non-
DAR in the three pedal arch groups on the rate of healing
and time to healing in patients with foot tissue loss (only
Rutherford 5 and 6) was also analyzed.
Amputation-free survival, deﬁned as the ﬁrst major
amputation above the ankle (ie, transfemoral or transtibial)
in the limb on which bypass was performed (ie, ipsilateral
limb), or death from any cause—whichever occurred
ﬁrst—was chosen as an end point for its clear clinical signif-
icance. Similarly, amputation-free survival was chosen as an
end point in the Bypass Versus Angioplasty in Severe
Ischaemia of the Leg (BASIL) trial.11Patency rates were deﬁned according to the Rutherford
reporting standards,12 and were reported for 1 year only
because the graft duplex surveillance program was only
performed for 1 year.
Kaplan-Meier life-table analysis with the Mantel-Cox
log-rank test was used to analyze patency, amputation-
free survival, and healing rates for the pedal arch groups.
The Fisher exact test was used where appropriate. Values
of P < .05 were considered signiﬁcant. Statistical analysis
was performed using Prism 5.0 software (GraphPad
Software, Inc, La Jolla, Calif).
RESULTS
A total of 154 patients with CLI underwent 167 infra-
popliteal bypasses. Patients median age was 75 years
(range, 46-96 years), and 116 (75%) were men. Diabetes
mellitus was present in 127 (76%), chronic renal failure in
47 (28%), and ischemic heart disease in 74 (44%).
All patients included presented with CLI (Rutherford
4, 5, and 6). Tissue loss was present in 91 legs (54%),
toe gangrene requiring minor amputation in 50 (30%),
and rest pain in 26 (16%). Autogenous great saphenous
vein was used in 152 of 167 bypasses (91%), arm veins in
four (2%), and polytetraﬂuoroethylene with Miller’s cuff
in 11 (7%).
Fifty-three of the 167 legs had inﬂow disease on duplex
scan and underwent successful preoperative angioplasty.
Target arteries were two common iliac (4%), one external
iliac (2%), one common femoral (2%), 22 superﬁcial
Fig 3. No pedal arch (NPA).
Table I. Patient demographics and risk factors in the
pedal arch groups
Variablesa
CPA IPA NPA
(n ¼ 31) (n ¼ 104) (n ¼ 32)
Age, years 71 (51-86) 75 (46-90) 79 (55-96)
Men 27 (87) 73 (70) 28 (88)
Diabetes mellitus 24 (77) 78 (75) 23 (72)
Renal insufﬁciency 10 (32) 27 (26) 10 (31)
Hypertension 24 (77) 85 (82) 29 (91)
Ischemic heart disease 14 (45) 42 (40) 16 (50)
Smokers/former smokers 25 (81) 64 (62) 14 (44)
CPA, Complete pedal arch; IPA, incomplete pedal arch; NPA, no pedal
arch.
aContinuous data are given as median (range) and categoric data as number
(%).
Table II. Site of salvage angioplasty in the pedal arch
groups
Salvage
angioplasty
(N ¼ 85)
CPA (n ¼ 16),
No. (%)
IPA (n ¼ 52),
No. (%)
NPA (n ¼ 17),
No. (%)
Inﬂow 5 (31) 8 (15) 6 (35)
Graft 11 (69) 38 (73) 9 (53)
Outﬂow 0 (0) 6 (12) 2 (12)
CPA, Complete pedal arch; IPA, incomplete pedal arch; NPA, no pedal
arch.
Table III. Patency rates at 12 months and amputation-
free survival at 48 months in the pedal arch groups
Variable
CPA
(n ¼ 31),
%
IPA
(n ¼ 104),
%
NPA
(n ¼ 32),
% P
Primary patency 58.4 54.6 63.8 .5168
Assisted primary patency 86.0 82.0 88.8 .7170
Secondary patency 86.0 84.7 88.8 .8940
Amputation-free survival 67.2 69.7 45.9 .3883
CPA, Complete pedal arch; IPA, incomplete pedal arch; NPA, no pedal
arch.
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superﬁcial femoral artery/popliteal artery.
The site of the proximal anastomosis was the external
iliac artery in one (0.5%), common femoral artery in 33
(20%), deep femoral in one (0.5%), superﬁcial femoral in
54 (32%), above-knee popliteal artery in 18 (11%),
below-knee popliteal artery in 58 (35%), and the posterior
tibial artery in two (1%).
The site of the distal anastomosis was the tibioperoneal
trunk in 14 (9%), the anterior tibial artery in 45 (27%), the
peroneal artery in 30 (18%), the posterior tibial artery in 47
(28%), the dorsalis pedis in 24 (14%), and the plantar
arteries in seven (4%).
The overall mortality rates were 1% (2 of 167) at 30
days and 11% (19 of 167) at 1 year. Of the 167 bypasses,
DSA showed that 31 (19%) had CPA, 104 (62%) had
IPA, and 32 (19%) had NPA. The demographic character-
istics and risk factors (deﬁned and graded according to the
Society for Vascular Surgery/International Society for
Cardiovascular Surgery recommended criteria13) for the
CPA, IPA, and NPA groups are summarized in Table I.
Of the 167 grafts, 55 (33%) threatened grafts were
detected on the duplex scan surveillance program and
required 85 salvage angioplasties. Details of salvage angio-
plasty site in the CPA, IPA, and NPA groups are summa-
rized in Table II.
There was no statistically signiﬁcant difference between
the groups in the patency rate at 1-year and amputation-
free survival at 48 months (Table III). Details of theprimary patency, assisted primary patency, secondary
patency, and amputation-free survival rates are presented
in Table III and Figs 4-7.
Of the 167 bypasses, 141 performed for ischemic foot
tissue loss or gangrene (Rutherford 5 and 6) were analyzed
separately, taking into consideration the angiosome revas-
cularization theory. Patients presenting with rest pain
only (26 limbs of 167 limbs) were excluded from this anal-
ysis. Of the 141 in this cohort analysis, 78 underwent
minor amputation, 63 had ulcer debridement, and 18
patients underwent SSG in the foot for large tissue loss.
Full wound healing was achieved in 116 of the 141 patients
(82%), 10 wounds (7%) failed to heal, and 12 patients (9%)
died with nonhealed ulcers within 1 year after bypass.
Three patients (2%) were lost during follow-up. The major
Fig 4. Kaplan-Meier analysis of the primary patency rate with
standard error bars and number of subjects at risk (#SR) is shown
for those with complete pedal arch (CPA), incomplete pedal arch
(IPA), and no pedal arch (NPA).
Fig 5. Kaplan-Meier analysis of the assisted primary patency rate
with standard error bars and number of subjects at risk (#SR) is
shown for those with a complete pedal arch (CPA), incomplete
pedal arch (IPA), and no pedal arch (NPA).
Fig 6. Kaplan-Meier analysis of the secondary patency rate with
standard error bars and number of subjects at risk (#SR) is shown
for those with a complete pedal arch (CPA), incomplete pedal arch
(IPA), and no pedal arch (NPA).
Fig 7. Kaplan-Meier analysis of the amputation-free survival rate
with standard error bars and number of subjects at risk (#SR) is
shown for those with a complete pedal arch (CPA), incomplete
pedal arch (IPA), and no pedal arch (NPA).
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was 3% (4 of 141).
The site of tissue loss in the foot in the 141 patients
was 122 (86%) in the posterior tibial artery angiosome
territory compared to 14 (10%) in the ATA angiosome
territory and ﬁve (4%) in the peroneal artery angiosome
territory. CPA was present in 31 of 141 patients (22%)
compared with 88 (62%) with IPA and 22 (16%) with
NPA. Because of the distribution of the disease, direct
revascularization of the speciﬁc angiosome was only feasible
in 66 of 141 patients (47%) compared with the nonspeciﬁc
angiosome in 75 (53%). Complete foot wound healing was
achieved in 57 out of the 66 cases (86%) in the DAR groupcompared to 59 out of the 75 cases (79%) in the non-DAR
group (P ¼ .2736).
Details of healed wounds, time to healing, minor and
major amputation, graft occlusion at 1 year, patients dying
with nonhealed wounds at 1 year, SSG, and grade of
wounds according to Wagner wound classiﬁcation in the
three groups are summarized in Table IV and Table V.
SSGs were used liberally for wounds sized >7 cm in diam-
eter (15% in DAR vs 11% in non-DAR groups; P ¼ .4582).
There was signiﬁcant difference in the healing and the
time to healing between the CPA/IPA and the NPA
groups (P ¼ .0264; Fig 8).
Of 167 bypass grafts in the CPA group, two occluded
but no patients required major amputations. In the IPA
group, 19 grafts occluded and six patients underwent
Table IV. Details of direct angiosome revascularization (DAR) and non-DAR in the pedal arch groups
Pedal arch groups No.
Healed
Died non-H, No. SSG, No. 1-year GO, No.
Amputation
No. (%) Median days (range) Minor, No. Major, No.
CPA
DAR 18 15 (83) 66 (7-235) 3 2 1 9 0
Non-DAR 13 12 (92) 74 (7-541) 1 2 1 10 0
IPA
DAR 40 36 (90) 96 (7-647) 2 5 5 22 1
Non-DAR 48 39 (81) 86 (10-538) 3 5 7 24 3
NPA
DAR 8 6 (75) 90 (22-377) 0 3 1 5 0
Non-DAR 14a 8 (73) 135 (56-582) 3 1 0 8 0
Total bypasses 141
Died non-H, Patients died with non-healed ulcer; GO, graft occlusion; SSG, split-thickness skin graft.
aThree patients were lost to follow-up.
Table V. Wagner wound classiﬁcation grades in all
groups
Variable No.
Wagner wound classiﬁcation
Grade 2,
No. (%)
Grade 3,
No. (%)
Grade 4,
No. (%)
Grade 5,
No. (%)
CPA
DAR 18 7 (39) 6 (33) 5 (28) 0
Non-DAR 13 3 (23) 2 (15) 5 (38) 3 (23)
IPA
DAR 40 15 (38) 12 (30) 10 (25) 3 (8)
Non-DAR 48 20 (42) 13 (27) 13 (27) 2 (4)
NPA
DAR 8 2 (25) 4 (50) 2 (25) 0
Non-DAR 14 3 (21) 3 (21) 6 (43) 2 (14)
CPA, Complete pedal arch; DAR, direct angiosome revascularization; IPA,
incomplete pedal arch; NPA, no pedal arch.
Fig 8. Kaplan-Meier analysis of the healing rate and time to
healing with standard error bars and number of subjects at risk
(#SR) in complete pedal arch (CPA), incomplete pedal arch
(IPA), and no pedal arch (NPA) groups.
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between 10 and 223 days after the procedure; however,
by the time the grafts occluded, the ulcers had healed
and did not result in limb loss in these patients. Eight grafts
in the NPA group occluded, and one patient required
major amputation. Three of the eight grafts occluded
between 27 and 124 days after the bypass, with healed
ulcers.
DISCUSSION
The angiosome concept is an anatomic rather than
a physiologic study, as stated by Taylor and Palmer14 in
a letter published in 1992. The authors even stated that
they were careful not to make this extrapolation. Thus,
applying this concept wholly to patients with CLI may
not be as rewarding as hoped because these patients do
have generalized peripheral arterial disease spreading
down to the pedal arch.
We believe that direct revascularization as a concept is
acceptable, and all effort should be made when selecting
the target artery to consider the speciﬁc angiosome vessel.However, direct revascularization was only feasible in 47%
in this series, reﬂecting the severity of the crural arteries
disease in this group of patients. Similarly, a CPA was
only present in 19% of the cases, whereas 62% had IPA,
and the foot in 19% was perfused only through collateral
circulation rather than a named pedal artery. In our institu-
tion, a dedicated high-quality pedal arteries and foot arch
DSA is always obtained to help select the target vessel.
This is also supported by routine pedal arch duplex scan
when no runoff artery could be visualized on angiography.
On-table exploration of pedal vessels is also performed in
selected patients, as recommended by Pompeselli et al.15
This protocol has helped reduce the number of cases
deemed nonreconstructible on preoperative imaging.
The results of this study show that DAR did not inﬂu-
ence the outcome of distal bypass surgery in patients with
CLI. The time to healing did not differ between the
DAR and non-DAR groups except in the NPA group,
JOURNAL OF VASCULAR SURGERY
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results are similar to the study recently published by Azuma
et al.16 They concluded that the location and extent of the
ischemic wounds as well as comorbidities are more relevant
than the angiosome revascularized.
In this series, the quality of the pedal arch did not affect
the primary, assisted-primary, and secondary patency rates.
Similarly, the amputation-free survival between all pedal
arch groups did not show a statistically signiﬁcant differ-
ence. Previous studies have shown that the quality of the
runoff vessels can affect graft patency rates17,18; however,
in this series, this was not the case.
In their study published in 2006, Attinger et al2 stated
that the blood ﬂow to the foot and ankle is redundant
because the three major arteries feeding the foot have
multiple arterial–arterial connections. The “choke vessels”
described by Taylor and Palmer1 illustrate a type of
connection between different angiosomes; however, they
also stated that some connections are true anastomoses
without a change in arterial caliber, using the example of
the connection between the dorsalis pedis and the posterior
tibial arteries to demonstrate this type of anastomosis. We
fully agree with these conclusions and believe that in cases
where the arterial pedal arch is completely intact, the crural
artery perfused is irrelevant to the healing of tissue loss due
to these arterial–arterial connections between the three
main arteries of the leg, rendering the angiosome principle
irrelevant, too.
We are fully aware of the effect of other important
factors in wound healing, as highlighted by Azuma
et al.16 Different wound care techniques will also inﬂuence
the time to healing in these patients. In this series, SSG
were used liberally in patients with residual wounds >7
cm in diameter (15% in DAR vs 11% in non-DAR). This,
however, did not inﬂuence the outcome between the
groups.
Azuma et al16 demonstrated that the angiosome
perfused did not inﬂuence healing or amputation-free
survival in patients undergoing distal bypass surgery for
CLI. They, however, found that the degree of renal disease
in these patients had a direct effect on outcome, where
patients with end-stage renal disease had signiﬁcantly lower
healing and limb salvage rates compared with non-end-
stage renal disease patients. These results are similar to data
published by Pomposelli et al,19 and others,20-22 where
outcomes in these patients were less favorable than non-
end-stage renal disease patients. This could be explained by
the poor quality of the arterial pedal arch in these patients.23
There are several reports supporting DAR using endo-
vascular techniques.4,5 The “pedal-planter loop angio-
plasty” technique has also been described to reconstruct
the pedal arch in patients with CLI, with an 85% success
rate and a signiﬁcant improvement of transcutaneous
oxygen tension after the procedure.24 On the basis of the
results of the current series, where healing was signiﬁcantly
lower in patients with an IPA, we believe that the endovas-
cular reconstruction of the arterial pedal arch could reduce
the time to healing in patients with foot tissue loss.CONCLUSIONS
The quality of the pedal arch did not inﬂuence rates of
patency or amputation-free survival in patients undergoing
infrapopliteal bypass for CLI. However, the healing and
time to healing rates were directly inﬂuenced by the quality
of the pedal arch rather than the angiosome revascularized.
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